AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

By Maggie Fick LONDON, Aug 3 (Reuters) – AstraZeneca investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)